KANTUM PHARMA

Kantum is developing a specific AKI therapy to help critical care clinicians prevent hundreds of thousands of deaths from AKI. This targeted therapy will be supported by development of a novel diagnostic test for AKI. Kantum Bio is developing two programs in parallel: (1) Selective receptor antagonist-based therapeutics for AKI and (2) a UDP-G diagnostic test. Kantum’s lead therapeutic development candidate, KB-1801, will be developed for the prophylaxis and treatment of AKI secondary to card... iovascular intervention. Furthermore, KB-1801 has potential in cardiovascular accidents and other conditions associated with AKI in the ICU (e.g. sepsis, polytrauma, nephrotoxicity). The UDP-G diagnostic test will enable early diagnosis of patients at risk for AKI and may be leveraged to select patients and guide their treatment in clinical studies and, ultimately, in clinical practice.

#SimilarOrganizations #People #Financial #Website #More

KANTUM PHARMA

Industry:

Biopharma Biotechnology Health Care Therapeutics

Founded:

2016-01-01

Address:

Concord, New Hampshire, United States

Country:

United States

Website Url:

http://www.kantumpharma.com

Total Employee:

Status:

Active

Contact:

603-876-6200

Total Funding:

3.53 M USD

Technology used in webpage:

Wix Wix DNS

Similar Organizations

apellis-pharmaceuticals-logo

Current Employees Featured

glenn-v-batchelder_image

Glenn V. Batchelder
Glenn V. Batchelder Chairman @ Kantum Pharma
Chairman
2018-03-01

andrea-franz_image

Andrea Franz
Andrea Franz Chief Financial Officer @ Kantum Pharma
Chief Financial Officer

sylvie-breton_image

Sylvie Breton
Sylvie Breton Scientific founder @ Kantum Pharma
Scientific founder

Founder

sylvie-breton_image

Sylvie Breton

Investors List

broadview-ventures_image

Official Site Inspections

http://www.kantumpharma.com Semrush global rank: 6.11 M Semrush visits lastest month: 1.33 K

Host Informations
Whois Informations

Loading ...